T1	Participants 41 154	patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
T2	Participants 513 557	Nineteen patients with extremity melanoma (n
T3	Participants 558 583	= 16) or sarcoma (n = 3),
